The Gastric Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Gastric Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastric Cancer Market.

Some of the key takeaways from the Gastric Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Gastric Cancer treatment therapies with a considerable amount of success over the years. 
• Gastric Cancer companies working in the treatment market are Hubro Therapeutics, Cello Therapeutics, Idience, Leap Therapeutics, Eli Lilly and Company, BeiGene, Hutchison MediPharma, Astellas Pharma, Henlix Biotech, Jiangsu Hengrui Medicine, Neovii Biotech, Genmab/Janssen Biotech, Rapa Therapeutics LLC, HiberCell, Inc., and others, are developing therapies for the Gastric Cancer treatment 

• Emerging Gastric Cancer therapies in the different phases of clinical trials are- FMPV-1, CE008, Venadaparib, DKN-01, Abemaciclib, Tislelizumab, Fruquintinib, Zolbetuximab, HLX10, Camrelizumab, Catumaxomab, Amivantamab, RAPA-201, HC 5404 FU, and others are expected to have a significant impact on the Gastric Cancer market in the coming years.   
• In January 2022, Positive results from the global Phase III RATIONALE 305 study comparing tislelizumab to placebo in conjunction with chemotherapy as a first-line treatment for patients with metastatic or locally advanced, unresectable stomach or gastroesophageal junction (G/GEJ) cancer were released by BeiGene. Adenomatous cancer
• In December 2022, ENHERTU (trastuzumab deruxtecan), a product of Daiichi Sankyo and AstraZeneca, has been approved in the EU as a monotherapy for the treatment of adult patients with gastric or gastroesophageal junction (GEJ) adenocarcinomas that are advanced and have received a prior trastuzumab-based regimen.
• In December 2022, RemeGen Co., Ltd. announced that the US Food and Drug Administration (FDA) had granted two orphan drug designations (ODD) for pancreatic cancer and stomach cancer, including gastroesophageal junction cancer, for its most recent antibody-drug conjugate (ADC), RC118 for injection. After receiving two ODDs earlier this year for Telitacicept (RC18) and Disitamab Vedotin (RC48), this is the Company’s fourth.
• In December 2022, Zhejiang Doer Biologics Co., Ltd. announced that it has partnered with MSD (Merck & Co., Inc., Rahway, NJ, USA) on a clinical trial to study Doer Bio’s anti-Claudin18.2 antibody DR30303 in patients with gastric or gastroesophageal junction cancer in conjunction with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). As per the terms of this agreement, Doer Bio will carry out a clinical study based on a mutually decided upon and finalized protocol to assess the safety and effectiveness of DR30303 in combination with KEYTRUDA® in patients with gastric or gastroesophageal junction (GC/GEJ) cancer that is Claudin18.2-positive, locally advanced, incurable, or metastatic.
• In November 2022, Preclinical data regarding Triumvira Immunologics’ experimental TAC-T cell therapies, CLDN18.2-TAC T and GUCY2C-TAC T, as well as information on TAC-T products that are specific to the HER2 gene, were released. Three posters during the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which was held in person and online in Boston, featured data.For the purpose of treating stomach cancer, Triumvira has released new data on a unique T cell antigen coupler (TAC)-T cell candidate that targets Claudin 18.2 (CLDN18.2). The information keeps showing that CLDN18.2-TAC T efficiently eradicates gastric cancer cells that express CLDN18.2 both in vitro and in vivo. The investigation also showed that target cells expressing CLDN18.2 were the only ones that could activate CLDN18.2-TAC T cells. Strong and long-lasting anti-tumor action is shown by in vitro data, and in vivo treatment produced full and long-lasting
• In September 2022, Positive results with NXP800 in a preclinical xenograft model of gastric cancer with an ARID1a mutation were reported by Nuvectis Pharma, Inc.After receiving either NXP800 or a vehicle treatment, the tumor volumes of the mice in each group were measured during a 28-day period. Tumor growth inhibition was significant and tumor regression was observed after NX800 treatment in comparison to the control group.
• In March 2022, HER-2 positive gastric cancer patients will be the subjects of a new clinical trial collaboration and supply agreement between Imugene (ASX: IMU) and MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA. The purpose of the agreement is to assess the safety and effectiveness of Imugene’s B-cell activating immunotherapy, known as HER-Vaxx, in combination with MSD’s anti-PD-1 therapy, pembrolizumab (KEYTRUDA®).
• In January 2021, By inking a strategic collaboration agreement with BeiGene, Ltd. to in-license tislelizumab in significant regions outside of China, Novartis is stepping up its chances of breaking into the sizable and expanding checkpoint inhibitor market.

Gastric Cancer Overview

Gastric cancer, also known as stomach cancer, is a diverse illness that necessitates ongoing study and care in the areas of early detection, prevention, and cutting-edge treatment alternatives. The global distribution of GC varies significantly between geographical regions, demonstrating the wide range of factors that affect the disease’s incidence, survival, and death.

Get a Free Sample PDF Report to know more about Gastric Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/gastric-cancer-pipeline-insight

Emerging Gastric Cancer Drugs Under Different Phases of Clinical Development Include:

• FMPV-1: Hubro Therapeutics
• CE008: Cello Therapeutics
• Venadaparib: Idience
• DKN-01: Leap Therapeutics
• Abemaciclib: Eli Lilly and Company
• Tislelizumab : BeiGene
• Fruquintinib: Hutchison MediPharma
• Zolbetuximab: Astellas Pharma
• HLX10: Henlix Biotech
• Camrelizumab: Jiangsu Hengrui Medicine
• Catumaxomab: Neovii Biotech
• Amivantamab: Genmab/Janssen Biotech
• RAPA-201: Rapa Therapeutics LLC
• HC 5404 FU: HiberCell, Inc.

Gastric Cancer Route of Administration

Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Gastric Cancer Molecule Type

Gastric Cancer Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Gastric Cancer Pipeline Therapeutics Assessment

• Gastric Cancer Assessment by Product Type
• Gastric Cancer By Stage and Product Type
• Gastric Cancer Assessment by Route of Administration
• Gastric Cancer By Stage and Route of Administration
• Gastric Cancer Assessment by Molecule Type
• Gastric Cancer by Stage and Molecule Type

DelveInsight’s Gastric Cancer Report covers around 230+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Gastric Cancer product details are provided in the report. Download the Gastric Cancer pipeline report to learn more about the emerging Gastric Cancer therapies

Some of the key companies in the Gastric Cancer Therapeutics Market include:

Key companies developing therapies for Gastric Cancer are – EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp, and others.

Gastric Cancer Pipeline Analysis:

The Gastric Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Gastric Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastric Cancer Treatment.
• Gastric Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gastric Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastric Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Gastric Cancer drugs and therapies

Gastric Cancer Pipeline Market Drivers

• Increase in the number of patients suffering from Gastric Cancer, increasing awareness about the disease are some of the important factors that are fueling the Gastric Cancer Market.

Gastric Cancer Pipeline Market Barriers

• However, late diagnosis of the Disease, lengthier treatment duration and other factors are creating obstacles in the Gastric Cancer Market growth.

Scope of Gastric Cancer Pipeline Drug Insight    

• Coverage: Global
• Key Gastric Cancer Companies: Hubro Therapeutics, Cello Therapeutics, Idience, Leap Therapeutics, Eli Lilly and Company, BeiGene, Hutchison MediPharma, Astellas Pharma, Henlix Biotech, Jiangsu Hengrui Medicine, Neovii Biotech, Genmab/Janssen Biotech, Rapa Therapeutics LLC, HiberCell, Inc., and others
• Key Gastric Cancer Therapies: FMPV-1, CE008, Venadaparib, DKN-01, Abemaciclib, Tislelizumab, Fruquintinib, Zolbetuximab, HLX10, Camrelizumab, Catumaxomab, Amivantamab, RAPA-201, HC 5404 FU, and others
• Gastric Cancer Therapeutic Assessment: Gastric Cancer current marketed and Gastric Cancer emerging therapies
• Gastric Cancer Market Dynamics: Gastric Cancer market drivers and Gastric Cancer market barriers 

Request for Sample PDF Report for Gastric Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Gastric Cancer Report Introduction

2. Gastric Cancer Executive Summary

3. Gastric Cancer Overview

4. Gastric Cancer- Analytical Perspective In-depth Commercial Assessment

5. Gastric Cancer Pipeline Therapeutics

6. Gastric Cancer Late Stage Products (Phase II/III)

7. Gastric Cancer Mid Stage Products (Phase II)

8. Gastric Cancer Early Stage Products (Phase I)

9. Gastric Cancer Preclinical Stage Products

10. Gastric Cancer Therapeutics Assessment

11. Gastric Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Gastric Cancer Key Companies

14. Gastric Cancer Key Products

15. Gastric Cancer Unmet Needs

16 . Gastric Cancer Market Drivers and Barriers

17. Gastric Cancer Future Perspectives and Conclusion

18. Gastric Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services